Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Genetic Engineering News

06:03 EDT 17th July 2018 | BioPortfolio

Here are the most relevant search results for "Genetic Engineering News" found in our extensive news archives from over 250 global news sources.

More Information about Genetic Engineering News on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Genetic Engineering News for you to read. Along with our medical data and news we also list Genetic Engineering News Clinical Trials, which are updated daily. BioPortfolio also has a large database of Genetic Engineering News Companies for you to search.

Showing News Articles 1–25 of 962 from Genetic Engineering News

Monday 16th July 2018

Llama-Derived Nanobody May Tread Narrow Anticancer Path

Along the upper reaches of cell signaling loom the G protein-coupled receptors (GPCRs). From these serpentine structures descend pathways that diverge toward varied signaling outcomes, not all of which are desirable. For example, signaling cascades triggered by small-molecule drugs may lead to several types of cancer, neurological disorders, and drug addiction. Yet where small-molecule drugs may s...

Spero Wins Up to $54M Toward Development of Lead Antibiotic SPR994 for UTI

Spero Therapeutics said today it has won up to $54.2 million in grants from two federal agencies, and supporting studies by a third agency, toward further development of the company’s lead candidate SPR994 (tebipenem), an oral antibiotic for complicated urinary tract infections (cUTIs) caused by antibiotic resistant Gram-negative bacteria. The grants from the Biomedical Advanced Research and...

Biomarker’s Potential for Diagnosing Traumatic Brain Injury Solidified

Speed is key for medical diagnostics and critical for delivering the appropriate treatment in trauma cases—especially for neurological injuries. Identifying key markers for traumatic brain injury (TBI) is imperative since it is often difficult to evaluate the extent of damage or predict how long the impairment will last or whether it will worsen. Now, investigators from the David Geffen School o...

Fragile X Symptoms May be Helped with New Pharmacological Approach

Scientists report that a pharmacological strategy can alleviate multiple behavioral and cellular deficiencies in a mouse model of fragile X syndrome (FXS), the most common inherited form of intellectual disability and a major single-gene cause of autism spectrum disorders. The study (“ Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-ass...

Friday 13th July 2018

FDA Approves First Smallpox-Indicated Treatment, SIGA's TPOXX

The FDA today approved the first drug indicated for smallpox, SIGA Technologies’ TPOXX® (tecovirimat), which was developed with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). TPOXX is a small molecule antiviral therapy designed to mitigate the impact of a potential outbreak of smallpox. While the disease was declared t...

VC Investment More Than Doubles in Q2, Driven by Megadeals

Investor appetite for “megadeals” of $100 million or more grew during the second quarter, helping explain why biopharma venture capital investment more than doubled compared with a year ago, even as the number of deals stayed flat, according to a report released this week. Investors raised $4.047 billion in 126 biopharma VC deals during Q2 2018, according to the most recent quarterly PwC/C...

Human DNA Sentry Keeps Long Strands atop Watch List

Out-of-place DNA arouses the suspicion of a mammalian protein called cGAS, or cyclic GMP-AMP synthase. Although cGAS is usually as passive as a bored security guard, it leaps into action when it comes across DNA in the cell’s cytosol. Such DNA may indicate a foreign or cancerous intrusion. Curiously, the human version of cGAS has unique structural features that keep it on the lookout for lon...

Deletion of Addiction Gene Keeps Mice off Cocaine

European researchers have discovered how a gene that has previously been implicated in cancer plays a key role in certain regions of the brain in the control of cocaine addiction in mice. Studies headed by a team at the Université Libre de Bruxelles (ULB) in Belgium showed that animals lacking the melanoma antigen gene (Mage) known as Maged1 were unresponsive to cocaine, and didn’t develop ...

Novel RNA-based Vaccine Provides Protection Against Malaria

Generating vaccines toward eukaryotic pathogens has always presented challenges for researchers. While single-celled eukaryotic parasites, such as those that cause malaria may not seem close to humans evolutionarily, at the cellular level vaccine targets become limited due to homology with host molecules. However, now a team of investigators at Yale University has identified a novel target within ...

Cancer Drug Effectiveness Evaluated Using New Methodology

Researchers report the development of a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumor in real time, revealing which cells interact with the drug and which cells the drug fails to reach, according to the scientists. In the future, the findings (“ Heterogeneity in tumor chromatin-doxorubicin binding ...

Addiction to Cocaine Prevented by Deleting Single Gene in Mouse Brain

European researchers have discovered how a gene that has previously been implicated in cancer plays a key role in certain regions of the brain in the control of cocaine addiction in mice. Studies headed by a team at the Université Libre de Bruxelles (ULB) in Belgium showed that animals lacking the melanoma antigen gene (Mage) known as Maged1 were unresponsive to cocaine, and didn’t develop ...

New Method Developed to Help Determine Effectiveness of Cancer Drugs

Researchers report the development of a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumor in real time, revealing which cells interact with the drug and which cells the drug fails to reach, according to the scientists. In the future, the findings (“ Heterogeneity in tumor chromatin-doxorubicin binding ...

Thursday 12th July 2018

Effects of Genetic Mutations in PIK3CA on Glioblastoma Drug Treatment

A group of researchers from the University of North Carolina Lineberger Comprehensive Cancer Center have looked into how different mutations in a specific gene help drive glioblastoma (GBM). They showed that mutational status was not linked to a response to a single targeted drug, but it was to a combination of treatments. They used single agent and combination PI3K/MEK inhibitors buparlisib and s...

GSK Sells Psoriasis/Dermatitis Candidate Tapinarof to Dermavant

GlaxoSmithKline (GSK) said today that it has sold mostly-global rights to its Phase III-bound psoriasis and atopic dermatitis candidate tapinarof (GSK2894512) to Dermavant Sciences for up to £250 million ($330 million). Dermavant, a Roivant Sciences company focused on dermatology treatments, bought rights to tapinarof that cover all countries except China. However, Dermavant bought global...

Nonviral CRISPR Technology Developed for Faster, Cheaper T-Cell Engineering

Researchers at the University of California, San Francisco (UCSF) have developed what they describe as a fast, simple CRISPR -based method for genetically reprogramming T cell function, without using viral vectors. The technique, developed in the laboratory of associate professor of microbiology and immunology Alex Marson, M.D., Ph.D., uses electroporation to permeabilize T cells to the CRISPR gen...

Genmab, Immatics Launch Up-to-$2.8B+ Cancer Immunotherapy Partnership

Genmab will partner with Immatics Biotechnologies to discover and develop next-generation bispecific cancer immunotherapies through a collaboration that could generate more than $2.8 billion for Immatics, the companies said today. The companies have launched a research collaboration designed to combine Genmab's technologies and antibody expertise with Immatics' XPRESIDENT ® targe...

Nonviral CRISPR Technology Developed for Faster, Cheaper T Cell Engineering

Researchers at the University of California, San Francisco (UCSF) have developed what they describe as a fast, simple CRISPR-based method for genetically reprogramming T cell function, without using viral vectors. The technique, developed in the laboratory of associate professor of microbiology and immunology Alex Marson. M.D., Ph.D., uses electroporation to permeabilize T cells to the CRISPR gene...

Immunotherapy Boosts Survival Rates of Melanoma Brain Metastases’ Patients

A team led by researchers at Brigham and Women's Hospital reports that checkpoint blockade immunotherapies provided significant improvements in overall survival for patients with melanoma brain metastases. Their results (“ Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort ”) are published in&...

Wednesday 11th July 2018

Cancer-Linked Rearrangements Pepper Genome’s Regulatory Regions

When cancer is studied at the genomic level, certain variations tend to receive a lot of attention, chiefly the variations affecting protein-coding genes, which include variations such as point mutations and copy number alterations. Yet variations that affect non-protein–coding parts of the genome matter, too. But how much do they matter? The question has persisted, even while genomic inform...

Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms

Otsuka Pharmaceutical has agreed to acquire Visterra for approximately $430 million cash, the companies said today, in a deal that expands the pipeline of Otsuka and aligns with its goal of enhancing its drug discovery and development platforms. Through the acquisition, Otsuka will inherit Visterra’s Hierotope ® platform, intended to design and engineer precision antibody-based therapie...

Anti-Cancer Drug Effects Measured at Single-Cell Level by Multidimensional Technique

University of Zurich (UZH) scientists say they have developed a technique that makes it possible to quickly test various drugs at the cellular level. The method sheds light on the effects of anticancer drugs and the defense mechanisms of cancer cells, according to the researchers. The team uses cancer cell cultures to investigate the effects of PARP inhibitors, which make it difficult for...

Cause of CRISPR Failure Identified and Reversed

The clustered regularly interspaced short palindromic repeats ( CRISPR ) system has evolved in bacteria as a form of adaptive immune system, which scientists have customized as a versatile tool for gene editing cells in vitro, and potentially in vivo to correct diseases caused by gene mutations. However, CRISPR gene editing using the bacterially derived Cas9 nuclease enzyme isn’t foolproof and t...

New Technique Quickly Tests Effects of Anticancer Drugs at Cellular Level

University of Zurich (UZH) scientists say they have developed a technique that makes it possible to quickly test various drugs at the cellular level. The method sheds light on the effects of anticancer drugs and the defense mechanisms of cancer cells, according to the researchers. The team uses cancer cell cultures to investigate the effects of PARP inhibitors, which make it difficult for...

Tuesday 10th July 2018

Lifespan Extended, Health Improved by Senolytic Drugs

They’ve stopped dividing, yet they refuse to die. No, they’d rather persist in a zombie-like state, secreting pro-inflammatory factors, worsening age-related conditions, and accelerating aging itself. They are senescent cells, and getting rid of them is a tempting prospect, especially now that an experimental drug combination has been shown to benefit both artificially and naturally aged mice,...

Huntington’s Treatment May Come from Fix of Broken DNA Repair Mechanism

There is no treatment currently available to alter the course of Huntington’s disease (HD,) a hereditary neurodegenerative illness that results in uncontrolled movements, emotional problems and loss of cognition. A Canadian group of researchers is working to change that, with a new theory about the cause of HD that may lead to a potential path for a treatment. Their latest paper, entitle...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks